# Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.

> **NCT04474262** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 150 (estimated)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **BIOLOGICAL:** Albumin
- **DRUG:** Midodrine Oral Tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04474262
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-15
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474262, "Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04474262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*